Scholarlink

Abstract <p>Novel 1-[(1-phenyl-1<i>H</i>-1,2,3-triazol-5-yl)methyl]-4-(pyridin-2-yl)piperazine hybrids (<b>7a</b>–<b>7h</b>) were synthesized from 1-(2-pyridyl)piperazine and aromatic azides by click chemistry reaction in presence of Cu(II) and aqueous sodium ascorbate as catalyst. The <sup>1</sup>H and <sup>13</sup>C NMR and mass spectral techniques were used to characterize the newly obtained hybrids. The analogues were also screened for in vitro anticancer activity, and the results were correlated with molecular docking studies. Compounds having nitro group on the phenyltriazole moiety were found to be the most active against the tested cancer cell. The docking studies of these hybrids revealed that compound <b>7a</b> has greater affinity for the target receptor 4XO6 (MCF-7) and 5EQG (HepG2) proteins. These results emphasize the potential of 1-[(1-phenyl-1<i>H</i>-1,2,3-triazol-5-yl)methyl]-4-(pyridin-2-yl)­piperazine hybrids, making them strong contenders for further studies with the goal of developing more potent biological agents.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis, Anticancer Evaluation, and In Silico Docking Studies of 1-[(1-Phenyl-1H-1,2,3-triazol-5-yl)methyl]-4-(pyridin-2-yl)­piperazine Hybrids as Potential MCF Antagonists

  • 期刊论文

  • 发表日期：

    2025年10月1日

查看全文
  • B. Lakshmana,
  • S. Anandan,
  • P. Sathishbabu,
  • J. Rangaswamy,
  • C. Mahendra,
  • K. Mahesha,
  • M. S. Suresha,
  • Y. B. Basavaraju

摘要

Abstract

Novel 1-[(1-phenyl-1H-1,2,3-triazol-5-yl)methyl]-4-(pyridin-2-yl)piperazine hybrids (7a–7h) were synthesized from 1-(2-pyridyl)piperazine and aromatic azides by click chemistry reaction in presence of Cu(II) and aqueous sodium ascorbate as catalyst. The 1H and 13C NMR and mass spectral techniques were used to characterize the newly obtained hybrids. The analogues were also screened for in vitro anticancer activity, and the results were correlated with molecular docking studies. Compounds having nitro group on the phenyltriazole moiety were found to be the most active against the tested cancer cell. The docking studies of these hybrids revealed that compound 7a has greater affinity for the target receptor 4XO6 (MCF-7) and 5EQG (HepG2) proteins. These results emphasize the potential of 1-[(1-phenyl-1H-1,2,3-triazol-5-yl)methyl]-4-(pyridin-2-yl)­piperazine hybrids, making them strong contenders for further studies with the goal of developing more potent biological agents.